Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 16/20 | 0.40 |
| ▸ | MMP3 | P08254 | 4/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | FCER2 | P06734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552925 | 0.93 | MMP3 (0.47) | PTPN1MMP1MMP3MMP2MMP9 | |
| SCHEMBL5556531 | 0.85 | MMP2 (0.43) | PTPN1MMP1MMP3MMP2MMP7 | |
| SCHEMBL5552457 | 0.81 | KLKB1 (0.44) | MMP1MMP3MMP2MMP7MMP8 | |
| SCHEMBL5556372 | 0.81 | KLKB1 (0.44) | MMP1MMP3MMP2MMP7MMP8 | |
| SCHEMBL5557789 | 0.80 | CTSB (0.40) | MMP3MMP2MMP8MMP9 | |
| SCHEMBL5556660 | 0.79 | MMP2 (0.50) | PTPN1MMP1MMP3MMP2MMP7 | |
| SCHEMBL5552367 | 0.76 | MMP2 (0.46) | PTPN1MMP1MMP3MMP2MMP7 | |
| SCHEMBL5557632 | 0.76 | MMP9 (0.46) | PTPN1MMP1MMP3MMP2MMP8 | |
| SCHEMBL5552462 | 0.75 | TDP1 (0.43) | MMP3MMP2 | |
| SCHEMBL5556679 | 0.75 | KLKB1 (0.44) | PTPN1MMP1MMP3MMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | PTPN1 4197/4885MMP1 950/4885MMP3 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.